注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
上海君实生物科技有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Jun Xiong | 48 | 2015 | Executive Chairman |
Cong Li | 60 | 2016 | Co-CEO & Executive Director |
Jianjun Zou | 52 | 2022 | GM, CEO & Executive Director |
Yi Tang | 56 | 2015 | Non-Executive Director |
Zhi Qian | 56 | 2018 | Independent Non-Executive Director |
Hui Feng | 48 | 2015 | Non-Executive Director |
Roy Steven Herbst | 61 | 2018 | Independent Non-Executive Director |
Pingping Wang | 42 | 2018 | Non-Employee Representative Supervisor |
Sheng Yao | 49 | 2016 | Senior VP & Executive Director |
Zhuobing Zhang | 57 | 2016 | Deputy GM & Executive Director |
Gang Wang | 67 | 2019 | Deputy GM, Chief Quality Officer, Senior VP of Industry Affairs & Executive Director |
Yu Wu | 39 | 2018 | Chairman of the Board of Supervisors |
Ning Li | 63 | 2018 | Executive Vice-Chairman of the Board |
Chun Zhang | 67 | 2020 | Independent Non-Executive Director |
Xin Li | 45 | 2023 | Executive Director |
Yilian Huo | 33 | 2021 | Employee Representative Supervisor |
Anming Meng | 61 | 2023 | Independent Non-Executive Director |
Xiaoyuan Feng | 68 | 2021 | Independent Non-Executive Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核